Analysts Set Evommune, Inc. (NYSE:EVMN) Target Price at $49.67

Shares of Evommune, Inc. (NYSE:EVMN) have earned a consensus rating of “Moderate Buy” from the twelve analysts that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have assigned a buy rating and two have issued a strong buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $49.6667.

Several research firms have issued reports on EVMN. Royal Bank Of Canada raised Evommune to a “moderate buy” rating in a report on Tuesday, March 10th. Morgan Stanley reissued an “overweight” rating and set a $54.00 price objective on shares of Evommune in a research note on Wednesday, February 18th. Wall Street Zen upgraded Evommune from a “sell” rating to a “hold” rating in a report on Sunday, December 14th. The Goldman Sachs Group raised Evommune to a “buy” rating in a research report on Wednesday, January 7th. Finally, Evercore reaffirmed an “outperform” rating and set a $55.00 target price on shares of Evommune in a report on Tuesday, February 10th.

Institutional Trading of Evommune

Hedge funds have recently bought and sold shares of the company. XTX Topco Ltd acquired a new position in shares of Evommune in the fourth quarter worth about $321,000. Tudor Investment Corp ET AL acquired a new stake in shares of Evommune during the fourth quarter valued at approximately $547,000. Sphera Funds Management LTD. purchased a new stake in shares of Evommune in the 4th quarter valued at approximately $2,844,000. RTW Investments LP acquired a new position in Evommune in the 4th quarter worth approximately $21,976,000. Finally, Oxford Asset Management LLP acquired a new position in Evommune in the 4th quarter worth approximately $335,000.

Evommune Price Performance

Shares of EVMN opened at $24.99 on Wednesday. The stock has a 50 day simple moving average of $23.00. Evommune has a 12-month low of $13.89 and a 12-month high of $33.20. The firm has a market cap of $900.00 million and a PE ratio of -3.10.

Evommune (NYSE:EVMN) last released its earnings results on Thursday, March 5th. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.61).

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.